Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
29.36 USD | +1.87% | -1.04% | +272.12% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 7.33M | Capitalization | 442M |
---|---|---|---|---|---|
Net income 2024 * | -71M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 60.3 x |
P/E ratio 2024 * |
-5.9
x | P/E ratio 2025 * |
-7.47
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.22% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +1.87% | ||
1 week | -1.04% | ||
Current month | +38.16% | ||
1 month | +46.80% | ||
3 months | +308.97% | ||
6 months | +332.27% | ||
Current year | +272.12% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 29.36 | +1.87% | 95,945 |
24-03-27 | 28.82 | +3.33% | 69,788 |
24-03-26 | 27.89 | +0.69% | 80,735 |
24-03-25 | 27.7 | -5.23% | 135,009 |
24-03-22 | 29.23 | -1.48% | 55,779 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+272.12% | 442M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |